Maa: Irlanti
Kieli: englanti
Lähde: HPRA (Health Products Regulatory Authority)
NABUMETONE
Meda Health Sales Ireland Limited
M01AX01
NABUMETONE
500 MG/5ml
Oral Suspension
Product subject to prescription which may be renewed (B)
nabumetone
Not Marketed
1990-12-17
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Relifex 500 mg / 5 ml oral suspension 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5ml of suspension contains 500 mg nabumetone. _For full list of excipients, see section 6.1._ 3 PHARMACEUTICAL FORM Oral suspension. White to off-white suspension. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the symptomatic management of various arthritides, such as rheumatoid arthritis, osteoarthritis, spondylitis, gout, etc., and of acute musculoskeletal disorders. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Route of administration Oral. Recommended Dosage Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms_ (see section 4.4)._ Adults: The recommended daily dose is 10 ml (1g) taken as a single night time dose. For severe or persistent symptoms, or during acute exacerbations, an additional 5 ml or 10 ml (500 mg to 1g) may be given as a morning dose. Elderly: Total daily dosage should not exceed 1g. Non-steroidal anti-inflammatory drugs should be used with particular caution in elderly patients who are more prone to adverse events. The lowest dose compatible with adequate safe clinical control should be employed. _(See also section_ _4.4)._ Prolonged use of non-steroidal anti-inflammatory drugs is not recommended in the elderly. However, where prolonged treatment proves necessary, patients should be reviewed regularly. Children: There are no clinical data to recommend use of ‘Relifex’ in children. Where appropriate for acute conditions, including sports injuries, 10ml (1g) may be given as a loading dose. Total dosage should not exceed 2g a day. Treatment should be reviewed at regular intervals and discontinued if no benefit is seen or intolerance occurs. I R I S H M E D I C I N E S B O A R D ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ Lue koko asiakirja